Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5606056 | 1.00 | EPHX1 (0.46) | EPHX1GAASMYD3ALDH1A1EPHX2 | |
| SCHEMBL5605682 | 0.86 | EPHX1 (0.49) | EPHX1GAASMYD3ALDH1A1EPHX2 | |
| SCHEMBL5605675 | 0.86 | EPHX1 (0.49) | EPHX1GAASMYD3ALDH1A1EPHX2 | |
| SCHEMBL3225073 | 0.79 | EPHX1 (0.50) | EPHX1GAASMYD3ALDH1A1EPHX2 | |
| SCHEMBL2941951 | 0.76 | SMN1; SMN2 (0.47) | SMYD3ALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL2941952 | 0.76 | SMN1; SMN2 (0.47) | SMYD3ALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL25501931 | 0.74 | SMN1; SMN2 (0.55) | EPHX1GAASMYD3SIGMAR1SMN1; SMN2 | |
| SCHEMBL2944522 | 0.73 | POLB (0.43) | GAASMYD3ALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL2944520 | 0.73 | POLB (0.43) | GAASMYD3ALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL12819735 | 0.73 | SMYD3 (0.56) | EPHX1GAASMYD3ALDH1A1SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7166594-B2 | Antibacterial activity | AVENTIS PHARMA S.A. (FR) | 2007-01-23 | — | — | US | disclosed |
| US-20030149004-A1 | Streptogramin derivatives, their preparation and compositions containing them | AVENTIS PHARMA S.A. | 2003-08-07 | — | — | US | disclosed |
| US-6569854-B1 | Virginamycins | AVENTIS PHARMA S.A. (FR) | 2003-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030149004-A1 | Streptogramin derivatives, their preparation and compositions containing them | MRPL21, ABHD5, APEH | EPHX1 2734/4885GAA 2464/4885SMYD3 1499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.